Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies

dc.creatorCabral, Vanderlea Poeys
dc.creatorAndrade, Carlos Augusto Ferreira de
dc.creatorPassos, Sonia Regina Lambert
dc.creatorMartins, Maria de Fátima Moreira
dc.creatorHökerberg, Yara Hahr Marques
dc.date2019-02-27T13:05:51Z
dc.date2019-02-27T13:05:51Z
dc.date2016
dc.date.accessioned2023-09-27T00:11:26Z
dc.date.available2023-09-27T00:11:26Z
dc.identifierCABRAL, Vanderlea Poeys et al. Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. Revista Brasileira de Reumatologia, v. 56, n. 6, p. 543–550, 2016.
dc.identifier0482-5004
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/31890
dc.identifier10.1016/j.rbre.2016.10.001
dc.identifier1809-4570
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8898347
dc.descriptionA question is raised about an increased risk of severe infection from the use of biological drugs in patients with rheumatoid arthritis. This systematic review of observational studies aimed at assessing the risk of severe infection associated with the use of anakinra, rituximab, and abatacept in patients with rheumatoid arthritis. The following databases were searched: PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, Exerpta Medica Database, Scielo, and Lilacs up to July 2010. Severe infections were defined as those life-threatening ones in need of the use of parenteral antibiotics or of hospitalization. Longitudinal observational studies were selected without language restriction, involving adult patients diagnosed with rheumatoid arthritis and who used anakinra, rituximab, or abatacept. In four studies related to anakinra, 129 (5.1%) severe infections were related in 2896 patients, of which three died. With respect to rituximab, two studies reported 72 (5.9%) severe infections in 1224 patients, of which two died. Abatacept was evaluated in only one study in which 25 (2.4%) severe infections were reported in 1046 patients. The main site of infection for these three drugs was the respiratory tract. One possible explanation for the high frequency of severe infections associated with anakinra may be the longer follow-up time in the selected studies. The high frequency of severe infections associated with rituximab could be credited to the less strict inclusion criteria for the patients studied. Therefore, infection monitoring should be cautious in patients with rheumatoid arthritis in use of these three drugs.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectRheumatoid arthritis/therapy
dc.subjectAnti-rheumatic drugs/adverse effects
dc.subjectInfection
dc.subjectBiological therapy/adverse effects
dc.subjectReview of literature as topic
dc.titleSevere infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies
dc.typeArticle


Este ítem pertenece a la siguiente institución